Pascal Soriot, CEO of the company noted he was excited about the acceleration of the companys cardiometabolic and obesity pipeline with the licensing agreement for ECC5004, a potential best-in-class oral GLP-1RA. ECC5004 has an oral formulation, in contrast to Novo Nordisks Wegovy (semaglutide) and the recently approved Lillys Zepbound (tirzepatide), which are injectables
Mayo Clinic: Pros and Cons of GLP-1 Agonists for Weight Loss Johns Hopkins Medicine: Maintaining Weight Loss Yale Medicine: GLP-1 Medications for Weight Loss: How to Get Started Harvard Health Publishing: Do GLP-1 Drugs Reduce Inflammation
Leukemia and other bone marrow disorders can reduce platelet production and affect normal blood cell formation
Were excited to partner with Novo Nordisk to offer the first GLP-1 cash price on our platform for both Ozempic and Wegovy, she said
Want to be notified when this product is back in stock
thus, it blunts the decline in postprandial blood glucose